ntroduction: The chemotherapy of solid primary tumors with or without liver metastasis, very often impairs liver function causing high level of transaminase, GGT, bilirubin, alkaline phosphatase, and low albumin level due to intrinsic toxicity. The concept to add UDCA during or after chemotherapy cycles whenever liver toxicity risk is reasonably high, or impending, or already stabilized with variable digestive symptoms and low life quality, is nowadays very appealing.